Cargando…

Benefit-harm analysis and charts for individualized and preference-sensitive prevention: example of low dose aspirin for primary prevention of cardiovascular disease and cancer

BACKGROUND: Clinical practice guidelines provide separate recommendations for different diseases that may be prevented or treated by the same intervention. Also, they commonly provide recommendations for entire populations but not for individuals. To address these two limitations, our aim was to con...

Descripción completa

Detalles Bibliográficos
Autores principales:	Puhan, Milo A., Yu, Tsung, Stegeman, Inge, Varadhan, Ravi, Singh, Sonal, Boyd, Cynthia M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4589917/ https://www.ncbi.nlm.nih.gov/pubmed/26423305 http://dx.doi.org/10.1186/s12916-015-0493-2

Ejemplares similares

Aspirin for Primary Prevention of Cardiovascular Disease and Cancer. A Benefit and Harm Analysis
por: Stegeman, Inge, et al.
Publicado: (2015)

Older adult preferences regarding benefits and harms of statin and aspirin therapy for cardiovascular primary prevention()
por: Wang, Frances M., et al.
Publicado: (2023)

A framework for organizing and selecting quantitative approaches for benefit-harm assessment
por: Puhan, Milo A, et al.
Publicado: (2012)

Quantitative benefit–harm assessment for setting research priorities: the example of roflumilast for patients with COPD
por: Puhan, Milo A., et al.
Publicado: (2015)

Should statin guidelines consider patient preferences? Eliciting preferences of benefit and harm outcomes of statins for primary prevention of cardiovascular disease in the sub-Saharan African and European contexts
por: Yebyo, Henock G., et al.
Publicado: (2018)

Net benefit of statins for primary prevention of cardiovascular disease in people 75 years or older: a benefit–harm balance modeling study
por: Yebyo, Henock G., et al.
Publicado: (2019)

Support of personalized medicine through risk-stratified treatment recommendations - an environmental scan of clinical practice guidelines
por: Yu, Tsung, et al.
Publicado: (2013)

Global variation of risk thresholds for initiating statins for primary prevention of cardiovascular disease: a benefit-harm balance modelling study
por: Yebyo, Henock G., et al.
Publicado: (2020)

Large-scale prevention trials could provide stronger evidence for decision-makers: Opportunities to design and report with a focus on the benefit–harm balance
por: Aschmann, Hélène E, et al.
Publicado: (2022)

Balance of benefits and harms of different blood pressure targets in people with multiple chronic conditions: a quantitative benefit-harm assessment
por: Aschmann, Hélène E, et al.
Publicado: (2019)

Critical Overview on the Benefits and Harms of Aspirin
por: Kwok, Chun Shing, et al.
Publicado: (2010)

Estimates of benefits and harms of prophylactic use of aspirin in the general population
por: Cuzick, J., et al.
Publicado: (2015)

Fingolimod versus interferon beta 1-a: Benefit–harm assessment approach based on TRANSFORMS individual patient data
por: Spanu, Alessandra, et al.
Publicado: (2022)

Iranian general populations' and health care providers' preferences for benefits and harms of statin therapy for primary prevention of cardiovascular disease
por: Saadati, Hassan, et al.
Publicado: (2020)

Aspirin for Prevention of Cardiovascular Disease
por: Mendy, Vincent L., et al.
Publicado: (2017)

Individualised benefit–harm balance of aspirin as primary prevention measure – a good proof-of-concept, but could have been better…
por: Thorat, Mangesh A.
Publicado: (2016)

Patient and General Population Preferences Regarding the Benefits and Harms of Treatment for Metastatic Prostate Cancer: A Discrete Choice Experiment
por: Menges, Dominik, et al.
Publicado: (2023)

Charting a path towards a public health approach for gambling harm prevention
por: Price, Alex, et al.
Publicado: (2021)

Fall prevention interventions for older community-dwelling adults: systematic reviews on benefits, harms, and patient values and preferences
por: Pillay, Jennifer, et al.
Publicado: (2021)

Aspirin for primary prevention of cardiovascular disease
por: Nansseu, Jobert Richie N., et al.
Publicado: (2015)

Aspirin for Primary Prevention of Cardiovascular Disease
por: Kim, Ji Hye, et al.
Publicado: (2019)

Aspirin in people with dementia, long-term benefits, and harms: a systematic review
por: Davis, Katrina A. S., et al.
Publicado: (2021)

Aspirin for Prevention of Preeclampsia
por: Atallah, A., et al.
Publicado: (2017)

Aspirin overutilization for the primary prevention of cardiovascular disease
por: VanWormer, Jeffrey J, et al.
Publicado: (2014)

Aspirin for primary prevention of cardiovascular disease in diabetes
por: Xing, Ying, et al.
Publicado: (2019)

Aspirin for the primary prevention of cardiovascular disease in the elderly
por: O’Sullivan, Jack W
Publicado: (2019)

Use and Misuse of Aspirin in Primary Cardiovascular Prevention
por: Coccheri, Sergio
Publicado: (2017)

Aspirin in the Modern Era of Cardiovascular Disease Prevention
por: Murphy, Ella, et al.
Publicado: (2021)

Aspirin in primary prevention of cardiovascular disease in diabetes
por: Papazafiropoulou, Athanasia K., et al.
Publicado: (2021)

Population Specific and Up to Date Cardiovascular Risk Charts Can Be Efficiently Obtained with Record Linkage of Routine and Observational Data
por: Faeh, David, et al.
Publicado: (2013)

Clinical Use of Aspirin in Treatment and Prevention of Cardiovascular Disease
por: Dai, Yuxiang, et al.
Publicado: (2012)

Esomeprazole and aspirin fixed combination for the prevention of cardiovascular events
por: Sylvester, Katelyn W, et al.
Publicado: (2013)

Use of Aspirin and Statin as primary prevention for cardiovascular diseases
por: Alkhail, Bahaa Aba, et al.
Publicado: (2016)

Aspirin use for cardiovascular disease prevention in the uninsured population
por: Liu, Nina, et al.
Publicado: (2020)

Aspirin Bioactivity for Prevention of Cardiovascular Injury in COVID-19
por: Diaz, Temistocles, et al.
Publicado: (2020)

Aspirin for Primary Prevention of Cardiovascular Diseases: “WALTZ” with the Evidence
por: Dimitriadis, Kyriakos, et al.
Publicado: (2022)

Primary care providers should prescribe aspirin to prevent cardiovascular disease based on benefit−risk ratio, not age
por: Kim, Kyungmann, et al.
Publicado: (2021)

Aspirin and prostate cancer prevention
por: Vidal, Adriana C., et al.
Publicado: (2015)

Aspirin for primary prevention in the elderly
por: Saad, Marwan, et al.
Publicado: (2019)

High prevalence of potential biases threatens the interpretation of trials in patients with chronic disease
por: Vollenweider, Daniela, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_ipf02743mfe46dupsd7su0g583